68 related articles for article (PubMed ID: 38758230)
1. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
Ringwalt EM; Currier MA; Glaspell AM; Chen CY; Cannon MV; Cam M; Gross AC; Gust M; Wang PY; Boon L; Biederman LE; Schwarz E; Rajappa P; Lee DA; Mardis ER; Carson WE; Roberts RD; Cripe TP
bioRxiv; 2024 Mar; ():. PubMed ID: 38464161
[TBL] [Abstract][Full Text] [Related]
4. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
Moura DS; Mondaza-Hernandez JL; Sanchez-Bustos P; Peña-Chilet M; Cordero-Varela JA; Lopez-Alvarez M; Carrillo-Garcia J; Martin-Ruiz M; Romero-Gonzalez P; Renshaw-Calderon M; Ramos R; Marcilla D; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ortega-Medina L; Martin-Davila F; Hernandez-Leon CN; Romagosa C; Salgado MAV; Lavernia J; Bagué S; Mayodormo-Aranda E; Alvarez R; Valverde C; Martinez-Trufero J; Castilla-Ramirez C; Gutierrez A; Dopazo J; Hindi N; Garcia-Foncillas J; Martin-Broto J
Cell Mol Life Sci; 2024 May; 81(1):219. PubMed ID: 38758230
[TBL] [Abstract][Full Text] [Related]
5. Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Sun CM; Toulmonde M; Spalato-Ceruso M; Peyraud F; Bessede A; Kind M; Cousin S; Buy X; Palussiere J; Bougouin A; Sautès-Fridman C; Fridman HW; Pulido M; Italiano A
Mol Cancer; 2024 Feb; 23(1):37. PubMed ID: 38374062
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma.
Martin-Broto J; Olarte-García A; Fernandéz-Rodríguez R; Ferreira MR; Carrasco-García I; Galvez-Montosa F; Rincon-Perez I; Peinado-Serrano J; Azinovic I; Guzman-Gomez L; Salgado L; Sevillano A; Ortega J; Alvarez C; Gutierrez A; Moura DS; Hindi N
Ther Adv Med Oncol; 2024; 16():17588359231225044. PubMed ID: 38288156
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin modulates macrophage polarization in the tumor-microenvironment. Role of K
Peraza DA; Povo-Retana A; Mojena M; García-Redondo AB; Avilés P; Boscá L; Valenzuela C
Biomed Pharmacother; 2023 May; 161():114548. PubMed ID: 36940615
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Balleyguier C; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bardet A; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Archambaud B; Duffaud F;
Lancet Oncol; 2022 Aug; 23(8):1044-1054. PubMed ID: 35835135
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance.
Rytlewski J; Brockman QR; Dodd RD; Milhem M; Monga V
Cancer Drug Resist; 2022; 5(1):25-35. PubMed ID: 35582536
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment.
Allavena P; Belgiovine C; Digifico E; Frapolli R; D'Incalci M
Front Oncol; 2022; 12():851790. PubMed ID: 35299737
[TBL] [Abstract][Full Text] [Related]
13. Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M; Laginestra MA; Durante G; Mancarella C; Landuzzi L; Parra A; Ruzzi F; Toracchio L; De Feo A; Giusti V; Pasello M; Righi A; Lollini PL; Palmerini E; Donati DM; Manara MC; Scotlandi K
Cancer Res; 2022 Feb; 82(4):708-720. PubMed ID: 34903601
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.
Martin-Broto J; Lopez-Alvarez M; Moura DS; Ramos R; Collini P; Romagosa C; Bagué S; Renne SL; Barisella M; Velasco V; Coindre JM; Lopez-Lopez D; Dopazo J; Gambarotti M; Braglia L; Merlo DF; Palmerini E; Stacchiotti S; Quagliuolo VL; Lopez-Pousa A; Grignani G; Blay JY; Brunello A; Gutierrez A; Valverde C; Hindi N; Dei Tos AP; Picci P; Casali PG; Gronchi A
Mol Cancer Ther; 2021 Dec; 20(12):2539-2552. PubMed ID: 34552008
[TBL] [Abstract][Full Text] [Related]
15. Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.
Pillozzi S; Bernini A; Palchetti I; Crociani O; Antonuzzo L; Campanacci D; Scoccianti G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207243
[TBL] [Abstract][Full Text] [Related]
16. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Moura DS; Peña-Chilet M; Cordero Varela JA; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ramos R; Ortega-Medina L; Martin-Davila F; Castilla-Ramirez C; Hernandez-Leon CN; Romagosa C; Vaz Salgado MA; Lavernia J; Bagué S; Mayodormo-Aranda E; Vicioso L; Hernández Barceló JE; Rubio-Casadevall J; de Juan A; Fiaño-Valverde MC; Hindi N; Lopez-Alvarez M; Lacerenza S; Dopazo J; Gutierrez A; Alvarez R; Valverde C; Martinez-Trufero J; Martín-Broto J
Mol Oncol; 2021 Dec; 15(12):3691-3705. PubMed ID: 33983674
[TBL] [Abstract][Full Text] [Related]
17. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology.
Lauder SN; Milutinovic S; Pires A; Smart K; Godkin A; Gallimore A
Methods Cell Biol; 2021; 163():59-75. PubMed ID: 33785169
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
Merry E; Thway K; Jones RL; Huang PH
NPJ Precis Oncol; 2021 Mar; 5(1):17. PubMed ID: 33674685
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
